Eli Lilly Stock News

Wall Street will navigate a series of key S&P 500 earnings Thursday as investors look to forward projections from a host of companies amid concerns of rising inflation, Federal Reserve rate hikes and slowing consumer growth.

Eli Lilly (LLY) is trading lower in the pre-market after missing its Q4 2021 earnings estimates

Eli Lilly Earnings, Revenue Beat in Q4

Eli Lilly press release (LLY): Q4 Non-GAAP EPS of $2.49 misses by $0.02.Revenue of $8B (+7.5% Y/Y) beats by $110M.2022 EPS guidance reaffirmed to be in the range of $8.00 to $8.15 on

Chinese Scientists Discover "Godsend" Antibody Cocktail That Can "Neutralize" Omicron After a long silence while Beijing insisted - more or less successfully - that SARS-CoV-2 had been annihilated in China, Chiese researchers have once again been producing a flurry of research on the virus''s origins, while also claiming new breakthroughs in treatment. They even went so far as to propose a new zoonotic link between the omicron variant and mice. On Wednesday, we saw that trend continue as a team of scientists from Fudan University claimed to have found a new "godsend" antibody that would magically neutralize omicron and all future strains. The "surprise" discovery was reportedly made while the team was investigating other strains of the virus, according to their research, which was published on Biorxiv. According to the leader of the team that carried out the research, the scientists crafted a new antibody cocktail synthesized from human cells produced in response to infections with other variants.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.

Eagle Pharmaceuticals (EGRX) announces the commercial availability of its novel product Pemfexy (pemetrexed for injection).A branded alternative to Eli Lilly''s Alimta, Eagles PEMFEXY is

Key Events This Week: ECB, BOE, Payrolls, Euro CPI And Earnings Galore It''s a relatively busy week with several key central bank announcements, notably from the ECB and BOE, as well as European CPI updates and the US payrolls report on Friday. Starting with the ECB, Deutsche Bank economists now expect a policy rate liftoff in December 2022 of 25bps, a view apparently shared by the market this morning. Theyre also anticipating a faster pace of tightening, with 25bp hikes in the deposit rate per quarter from December 2022, until rates reach +0.5% in September 2023. In terms of what it means for this February meeting, they write in their preview that they expect the slow, step-by-step pivot to exit will continue. Their view is that President Lagarde will reiterate the ECBs capacity to act once the inflation criteria in the rates guidance are met, whilst at the same time differentiating the needs of the Euro Area from the US. The other central bank decision that day is from the Bank of England, where expectations are for the BoE to follow up their December rate hike with another 25bps increase, taking the Bank Rate to 0.5%.

US Futures Start The Week With More Wild Swing In Another Volatile, Illiquid Session After a rollercoaster week that ended just barely higher following a late meltup on Friday, overnight volatile US stock futures swung to start the week, with Nasdaq 100 futures leading gains after rallying on Friday, before turning red and threatening to fizzle a global equity rally amid persistent worries over the Federal Reserve’s plan to hike interest rates this year. Emini S&P futures were down 0.5% or 21 points to 4401, after rising as high as 4437 and dropping as low as 4395 in another extremely illiquid session where China being offline for the week due to Lunar New Year did not help; Nasdaq futures were down 0.1% while Dow futures were lower 0.7%. Technology stocks led gains on the Stoxx Europe 600. Meanwhile, the dollar fell and oil rallied. As investors reconcile to a hawkish U.S. central bank coupled with strong earnings, the expensive parts of the U.S. stock market are undergoing a valuation re-rating along with the bond markets.

Eli Lilly And Co (NYSE: LLY ) plans to invest over $1 billion to create a new manufacturing site in the U.S, with nearly 600 new jobs in Concord, North Carolina. The new facility will manufacture parenteral (injectable) products and devices Full story available on Benzinga.com

Eli Lilly And Co (NYSE: LLY ) plans to invest more than 400 million into a new manufacturing facility in Limerick, Ireland, according to a report on gov.ie , a central portal for government services and information. The plant itself will employ more than 300 once it''s complete. In the meantime, Lilly plans to enlist some 500 temporary workers for the facility build. The Limerick plant will boost Lilly''s Full story available on Benzinga.com

Eli Lilly (LLY) plans to invest over $1B to create a new manufacturing site, along with nearly 600 new jobs, in Concord, North Carolina.The facility will utilize the latest technology

Eli Lilly (LLY) and Incyte (INCY) said the phase 3 development program for Olumiant (baricitinib) in lupus was being discontinued and that the application seeking approval of Olumiant

Lilly (LLY) announces that Health Canada has authorized Verzenio (abemaciclib) (tablets), in combination with endocrine therapy, for the adjuvant treatment of adult patients with